The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Authors
Keywords
-
Journal
Molecular Cancer
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-02
DOI
10.1186/s12943-020-01200-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
- (2019) Akinori Sasaki et al. Gastric Cancer
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs
- (2019) Betul Gok Yavuz et al. Scientific Reports
- Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
- (2019) James B. Wing et al. IMMUNITY
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria
- (2019) Ignacio Matos et al. CLINICAL CANCER RESEARCH
- Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine
- (2019) Hadi Hassannia et al. IMMUNOLOGY
- The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review
- (2019) Elissar Moujaess et al. Immunotherapy
- Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
- (2019) Samuel J. Klempner et al. ONCOLOGIST
- Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
- (2019) Tom J. Harryvan et al. Journal of Clinical Medicine
- The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma
- (2018) Anne M. Mills et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review
- (2018) Feifei Teng et al. CANCER LETTERS
- Nivolumab in squamous cell carcinoma of the head and neck
- (2018) Pol Specenier Expert Review of Anticancer Therapy
- IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling
- (2018) Yi Gao et al. INTERNATIONAL JOURNAL OF CANCER
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma
- (2018) Yusheng Cheng et al. Cell Death & Disease
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- (2018) Derin B. Keskin et al. NATURE
- Hyperprogressive disease: recognizing a novel pattern to improve patient management
- (2018) Stéphane Champiat et al. Nature Reviews Clinical Oncology
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma
- (2017) Sun Hye Kim et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
- (2017) Gustavo Schvartsman et al. LUNG CANCER
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death
- (2017) Emarndeena H Cheteh et al. Cell Death & Disease
- Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer
- (2017) Kenji Gonda et al. Oncology Letters
- Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells
- (2017) Paul E. Clavijo et al. Oncotarget
- Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy
- (2017) Daiki Ogawara et al. Thoracic Cancer
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Intracellular signalling pathways: targets to reverse immunosenescence
- (2016) T. Fulop et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
- (2016) M. Sade-Feldman et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Efficacy of PD-1 blockade in tumors with MMR deficiency
- (2016) Valerie Lee et al. Immunotherapy
- Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy
- (2016) Gregory S. Alexander et al. Journal of Hematology & Oncology
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation
- (2016) J-t Cheng et al. Oncogenesis
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset
- (2015) Gurcan Gunaydin et al. OncoImmunology
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors
- (2015) Lihua Huang et al. Acta Pharmaceutica Sinica B
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
- (2014) S. Nag et al. CURRENT MEDICINAL CHEMISTRY
- Regulation of the anti-tumour immune response by cancer-associated fibroblasts
- (2014) James Harper et al. SEMINARS IN CANCER BIOLOGY
- Depletion of Tumor-Associated Macrophages Slows the Growth of Chemically Induced Mouse Lung Adenocarcinomas
- (2014) Jason M. Fritz et al. Frontiers in Immunology
- Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
- (2014) Saskia JAM Santegoets et al. Journal for ImmunoTherapy of Cancer
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
- (2013) P. A. Ascierto et al. CLINICAL CANCER RESEARCH
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
- (2013) B. Weide et al. CLINICAL CANCER RESEARCH
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- The Effect of Age on Thymic Function
- (2013) Donald B. Palmer Frontiers in Immunology
- Human T Cell Aging and the Impact of Persistent Viral Infections
- (2013) T. Fülöp et al. Frontiers in Immunology
- A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
- (2011) S. Solito et al. BLOOD
- MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
- (2011) Yan Wan et al. BMC CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Maximizing Tumor Immunity With Fractionated Radiation
- (2011) Dörthe Schaue et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- How do Regulatory T Cells Work?
- (2009) A. Corthay SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation
- (2008) Y. Onishi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More